High throughput screening identifies ATP-competitive inhibitors of the NLRP1 inflammasome.

[1]  J. Bertin,et al.  Blau Syndrome, the prototypic auto-inflammatory granulomatous disease , 2014, Pediatric Rheumatology.

[2]  T. Monie.  NLR activation takes a direct route. , 2013, Trends in biochemical sciences.

[3]  B. Koller,et al.  NLRP1-Dependent Pyroptosis Leads to Acute Lung Injury and Morbidity in Mice , 2012, The Journal of Immunology.

[4]  Richard A Flavell,et al.  Innate instruction of adaptive immunity revisited: the inflammasome , 2009, EMBO molecular medicine.

[5]  T. Mogensen.  Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[6]  G. Núñez,et al.  The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis , 2009, Nature Immunology.

[7]  A. Prieur,et al.  Cryopyrinopathies: update on pathogenesis and treatment , 2008, Nature Clinical Practice Rheumatology.

[8]  N. Volkmann,et al.  Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. , 2007, Molecular cell.

[9]  M. Chamaillard,et al.  NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. , 2005, Annual review of biochemistry.

[10]  Yigong Shi,et al.  Structure of the apoptotic protease-activating factor 1 bound to ADP , 2005, Nature.

[11]  A. Ravelli.  Macrophage activation syndrome. , 2002, Current opinion in rheumatology.

[12]  A. Mustafa,et al.  Action of Hydrazines on Substituted 3,5-Pyrazolidinediones , 1961 .